TRAVERE THERAPEUTICS, INC. Deferred Income Tax Expense (Benefit)
TRAVERE THERAPEUTICS, INC. (TVTX) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-19
- TRAVERE THERAPEUTICS, INC. deferred income tax expense (benefit) for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. deferred income tax expense (benefit) for the quarter ending 2018-09-30 was $0.00.
- TRAVERE THERAPEUTICS, INC. deferred income tax expense (benefit) for the quarter ending 2018-06-30 was $0.00.
- TRAVERE THERAPEUTICS, INC. deferred income tax expense (benefit) for the quarter ending 2018-03-31 was $0.00.
- TRAVERE THERAPEUTICS, INC. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- TRAVERE THERAPEUTICS, INC. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- TRAVERE THERAPEUTICS, INC. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- TRAVERE THERAPEUTICS, INC. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 | ||||
| 2024-12-31 | $0.00 10-K · filed 2026-02-19 | ||||
| 2023-12-31 | $0.00 10-K · filed 2026-02-19 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-02-21 | ||||
| 2021-12-31 | $0.00 10-K · filed 2024-02-20 | ||||
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 derived: sum of 2 quarters · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | $1.39M derived: sum of 4 quarters · filed 2020-02-24 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $0.00 10-Q · filed 2018-08-03 | $1.39M derived: sum of 3 quarters · filed 2020-02-24 | -$1.00M derived: sum of 4 quarters · filed 2020-02-24 | |
| 2018-03-31 | $0.00 10-Q · filed 2018-07-06 | $1.39M derived: sum of 2 quarters · filed 2020-02-24 | -$1.00M derived: sum of 3 quarters · filed 2020-02-24 | -$4.36M derived: sum of 4 quarters · filed 2020-02-24 | |
| 2017-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | -$1.00M derived: sum of 2 quarters · filed 2020-02-24 | -$4.36M derived: sum of 3 quarters · filed 2020-02-24 | -$6.42M 10-K · filed 2020-02-24 | |
| 2017-09-30 | -$2.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$5.75M derived: sum of 2 quarters · filed 2018-11-01 | -$7.81M 10-Q · filed 2018-11-01 | -$19.47M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-06-30 | -$3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | -$5.42M 10-Q · filed 2018-08-03 | -$17.08M derived: sum of 3 quarters · filed 2019-02-26 | -$15.79M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-03-31 | -$2.06M 10-Q · filed 2018-07-06 | -$13.73M derived: sum of 2 quarters · filed 2019-02-26 | -$12.44M derived: sum of 3 quarters · filed 2019-02-26 | -$19.66M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2016-12-31 | -$11.66M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$10.38M derived: sum of 2 quarters · filed 2019-02-26 | -$17.59M derived: sum of 3 quarters · filed 2019-02-26 | -$22.66M 10-K · filed 2019-02-26 | |
| 2016-09-30 | $1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$5.93M derived: sum of 2 quarters · filed 2017-11-07 | -$11.00M 10-Q · filed 2017-11-07 | -$14.78M derived: sum of 4 quarters · filed 2018-07-06 | |
| 2016-06-30 | -$7.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$12.29M 10-Q · filed 2017-08-09 | -$16.07M derived: sum of 3 quarters · filed 2018-07-06 | $12.16M derived: sum of 4 quarters · filed 2018-07-06 | |
| 2016-03-31 | -$5.07M 10-Q · filed 2017-05-05 | -$8.85M derived: sum of 2 quarters · filed 2018-07-06 | $19.38M derived: sum of 3 quarters · filed 2018-07-06 | $19.38M derived: sum of 4 quarters · filed 2018-07-06 | |
| 2015-12-31 | -$3.78M derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-06 | $24.45M derived: sum of 2 quarters · filed 2018-07-06 | $24.45M derived: sum of 3 quarters · filed 2018-07-06 | -$15.57M 10-K · filed 2018-07-06 | |
| 2015-09-30 | $28.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $28.23M derived: sum of 2 quarters · filed 2016-11-04 | -$11.79M 10-Q · filed 2016-11-04 | -$14.25M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$40.02M 10-Q · filed 2016-08-05 | -$42.48M derived: sum of 3 quarters · filed 2017-03-01 | ||
| 2015-03-31 | -$40.02M 10-Q · filed 2016-05-05 | -$42.48M derived: sum of 2 quarters · filed 2017-03-01 | |||
| 2014-12-31 | -$2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$2.46M 10-K · filed 2017-03-01 | -$2.46K 10-K · filed 2015-03-11 | ||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-06 | ||||
| 2013-12-31 | -$9.73M 10-K · filed 2016-02-26 | -$9.73K 10-K · filed 2015-03-11 | |||
| 2012-12-31 | -$1.91M 10-K/A · filed 2015-07-09 | -$1.91K 10-K · filed 2013-06-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |